IDH2 and breast cancer: Moreover, elevated levels of 2HG in breast cancer cells without IDH mutation can be also driven by overexpression of the serine biosynthetic pathway enzyme phosphoglycerate dehydrogenase (PHGDH), which can catalyze the NADH-dependent reduction of αKG to 2HG [37].